Randomized Phase III Study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA)

Pegilodecakin (PEG) added to FOLFOX did not improve efficacy in advanced gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma. Overall survival was similar comparing PEG + FOLFOX versus FOLFOX (median: 5.8 v 6.3 months; hazard ratio = 1.045; 95% CI, 0.863 to 1.265).

Journal of Clinical Oncology